Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...
Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some ...
Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...
Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug ...
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...
Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...
Get detailed information on Rivaroxaban, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for ...
Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites. ‡Potent inhibitors of both CYP3A4 and P-gp include azole antifungals (e.g., ketoconazole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback